

Information For the User
Dapagliflozin (10mg) + Metformin (500mg) SR + Vildagliptin (100mg)

Dapoflit VM Tablet

Brand Name: Dapoflit VM Tablet

Dosage Form: Tablet

Composition:

Each film-coated tablet contains:

- Dapagliflozin IP 10 mg
- Metformin Hydrochloride IP 500 mg (Sustained Release)
- Vildagliptin IP 100 mg

Description:

Dapoflit VM Tablet is a fixed-dose combination of Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor; Metformin Hydrochloride, a biguanide; and Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. It is indicated for the management of type 2 diabetes mellitus in patients inadequately controlled on dual therapy. It helps in achieving improved glycemic control through complementary mechanisms, addressing fasting and post-prandial hyperglycemia effectively.

Indications:

Indicated for the treatment of:

- Type 2 diabetes mellitus
- Patients inadequately controlled on dual antidiabetic therapy

It helps in reducing blood glucose levels, improving insulin sensitivity, and enhancing incretin-mediated insulin secretion.

Dosage & Administration:

Dosage should be as directed by the physician.

The tablet should be swallowed whole with water, preferably with meals.

Do not crush or chew the sustained-release component.

Regular monitoring of blood glucose and renal function is recommended.

Pharmacological Action:

- **Dapagliflozin** reduces renal glucose reabsorption and increases urinary glucose excretion.
- **Metformin (Sustained Release)** decreases hepatic gluconeogenesis, improves peripheral insulin sensitivity, and reduces intestinal glucose absorption.
- **Vildagliptin** inhibits DPP-4 enzyme, increasing incretin hormones (GLP-1 and GIP), which enhance glucose-dependent insulin secretion and suppress glucagon release.

These combined mechanisms provide synergistic control of hyperglycemia.

Side Effects:

Common side effects include gastrointestinal disturbances, increased urination, hypoglycemia (especially when combined with other antidiabetic agents), genital infections, and mild dizziness.

Precautions & Warnings:

- Use with caution in patients with renal or hepatic impairment
- Monitor for hypoglycemia, particularly in elderly patients
- Risk of lactic acidosis associated with Metformin in predisposed patients
- Not indicated for type 1 diabetes mellitus or diabetic ketoacidosis

Drug Interactions:

Concomitant use with insulin or insulin secretagogues may increase the risk of hypoglycemia. Caution with drugs affecting renal function or CYP450 metabolism.

Storage:

Store below 25°C in a cool, dry place.

Protect from light and moisture.

Keep out of reach of children.

Manufactured in India for:



Cafoli Lifecare Pvt. Ltd.

(An ISO 9001: 2015 Certified Co.)

Plot no.: 367-FF, Industrial Area Phase-I,

Panchkula-134113

TM: Trademark Applied for